212) heir effector functions by decreasing the tumor infiltration of myeloid-derived supp |
213) 74 was not as effective in modulating the tumor infiltration of total CD3+ lymphocyt |
214) different cell types found in the bladder tumor microenvironment, RWFV-targeted LNPs |
215) y T-cell interactions with tumors and the tumor microenvironment, and how they can i |
216) -immunological biomarker encompassing the tumor microenvironment, disease staging an |
217) tition for glutamine may exist within the tumor microenvironment, potentially servin |
218) ppresses PD-L1 and PD-1 expression in the tumor microenvironment, suggesting that le |
219) vant chemotherapy has reduced the risk of tumor recurrence and improved survival in |
220) Furthermore, in a tumor recurrence model, photothermal-immun |
221) The high risk of tumor recurrence presents a big challenge |
222) a 4th surgery 25 years later for massive tumor recurrence. |
223) r stopping vemurafenib, there was massive tumor recurrence. |
224) nt in patients with cervical cancer were: tumor size <2 cm, tumor distance from |
225) ression of NBAT1 was also associated with tumor size and clinical TNM stages. |
226) section, positive lymph node numbers, and tumor size between LPD and OPD. |
227) RESULTS Mean tumor size did not differ between the 2 gr |
228) In multivariate analysis, larger tumor size was independently associated wi |
229) g biological and clinical insights beyond tumor type and histology in the pan-cancer |
230) is of epidemiological features (age, sex, tumor type and location, clinical presenta |
231) ty of the histological definition of this tumor type is helping these efforts but, d |
232) Bladder carcinoma is the most expensive tumor type to treat on a cost-per-patient |
233) be inconsistent and could be dependent on tumor type. |
234) ne glioma (DIPG) is a childhood brainstem tumor with a median overall survival of el |
235) is traditionally considered a glycolytic tumor with a poor prognosis while lacking |
236) cystic enhancing circumscribed brainstem tumor with high grade histopathology class |
237) Melanoma is an aggressive tumor with still poor therapy outcomes. |
238) 170 revealed strong efficacy against lung tumorigenesis with broad immunoregulatory |
239) Potential utility of circulating tumor DNA (ctDNA) prior to and post surger |
240) Circulating tumor DNA (ctDNA), circulating tumor cells |
241) , we used a target enrichment strategy on tumor DNA and RNA to isolate the viral seq |
242) Subclonal reconstruction from bulk tumor DNA sequencing has become a pillar o |
243) myeloma, treatment with BT-GSI decreased tumor burden and prevented the progression |
244) sed to TX20005 had a significantly higher tumor burden compared to saline-treated mi |
|